The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory Bowel Disease
Objectives. To determine the relationship between fecal calprotectin (FCAL) and imaging studies and other biochemical inflammatory markers and the impact of FCAL measurements on decision-making in IBD patient management in usual clinical practice. Methods. 240 persons with IBD were enrolled. The cor...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Canadian Journal of Gastroenterology and Hepatology |
| Online Access: | http://dx.doi.org/10.1155/2016/2483261 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832565525290418176 |
|---|---|
| author | Esmail Abej Wael El-Matary Harminder Singh Charles N. Bernstein |
| author_facet | Esmail Abej Wael El-Matary Harminder Singh Charles N. Bernstein |
| author_sort | Esmail Abej |
| collection | DOAJ |
| description | Objectives. To determine the relationship between fecal calprotectin (FCAL) and imaging studies and other biochemical inflammatory markers and the impact of FCAL measurements on decision-making in IBD patient management in usual clinical practice. Methods. 240 persons with IBD were enrolled. The correlation between FCAL values and other markers for disease activity such as serum albumin (alb), hemoglobin (Hg), and C-reactive protein (CRP) and diagnostic imaging or colonoscopy was examined. FCAL ≥ 250 mcg/g of stool was considered a positive result indicating active IBD. Results. 183 stool samples (76.3%) were returned. The return rate in the pediatric and adult cohorts was 91% (n=82) and 67.3% (n=101), respectively (P<0.0001). Positive FCAL was associated with colonoscopy findings of active IBD (P<0.05), low albumin (P<0.05), anemia (P<0.01), and elevated CRP (P<0.01). There was no significant difference for FCAL results by outcomes on small bowel evaluation among the 21 persons with small bowel CD. Most persons (87.5%) with normal FCAL and no change in therapy remained in remission during subsequent 3 months. Conclusions. FCAL is a useful marker of disease activity and a valuable tool in managing persons with IBD in clinical practice. Clinicians have to be cautious in interpreting FCAL results in small bowel CD. |
| format | Article |
| id | doaj-art-b01a2430540a4f13a16c53ce352f5ec5 |
| institution | Kabale University |
| issn | 2291-2789 2291-2797 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology and Hepatology |
| spelling | doaj-art-b01a2430540a4f13a16c53ce352f5ec52025-02-03T01:07:30ZengWileyCanadian Journal of Gastroenterology and Hepatology2291-27892291-27972016-01-01201610.1155/2016/24832612483261The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory Bowel DiseaseEsmail Abej0Wael El-Matary1Harminder Singh2Charles N. Bernstein3Section of Gastroenterology, Department of Internal Medicine, Winnipeg, MB, CanadaUniversity of Manitoba and the University of Manitoba IBD Clinical and Research Centre, Winnipeg, MB, CanadaSection of Gastroenterology, Department of Internal Medicine, Winnipeg, MB, CanadaSection of Gastroenterology, Department of Internal Medicine, Winnipeg, MB, CanadaObjectives. To determine the relationship between fecal calprotectin (FCAL) and imaging studies and other biochemical inflammatory markers and the impact of FCAL measurements on decision-making in IBD patient management in usual clinical practice. Methods. 240 persons with IBD were enrolled. The correlation between FCAL values and other markers for disease activity such as serum albumin (alb), hemoglobin (Hg), and C-reactive protein (CRP) and diagnostic imaging or colonoscopy was examined. FCAL ≥ 250 mcg/g of stool was considered a positive result indicating active IBD. Results. 183 stool samples (76.3%) were returned. The return rate in the pediatric and adult cohorts was 91% (n=82) and 67.3% (n=101), respectively (P<0.0001). Positive FCAL was associated with colonoscopy findings of active IBD (P<0.05), low albumin (P<0.05), anemia (P<0.01), and elevated CRP (P<0.01). There was no significant difference for FCAL results by outcomes on small bowel evaluation among the 21 persons with small bowel CD. Most persons (87.5%) with normal FCAL and no change in therapy remained in remission during subsequent 3 months. Conclusions. FCAL is a useful marker of disease activity and a valuable tool in managing persons with IBD in clinical practice. Clinicians have to be cautious in interpreting FCAL results in small bowel CD.http://dx.doi.org/10.1155/2016/2483261 |
| spellingShingle | Esmail Abej Wael El-Matary Harminder Singh Charles N. Bernstein The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory Bowel Disease Canadian Journal of Gastroenterology and Hepatology |
| title | The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory Bowel Disease |
| title_full | The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory Bowel Disease |
| title_fullStr | The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory Bowel Disease |
| title_full_unstemmed | The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory Bowel Disease |
| title_short | The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory Bowel Disease |
| title_sort | utility of fecal calprotectin in the real world clinical care of patients with inflammatory bowel disease |
| url | http://dx.doi.org/10.1155/2016/2483261 |
| work_keys_str_mv | AT esmailabej theutilityoffecalcalprotectinintherealworldclinicalcareofpatientswithinflammatoryboweldisease AT waelelmatary theutilityoffecalcalprotectinintherealworldclinicalcareofpatientswithinflammatoryboweldisease AT harmindersingh theutilityoffecalcalprotectinintherealworldclinicalcareofpatientswithinflammatoryboweldisease AT charlesnbernstein theutilityoffecalcalprotectinintherealworldclinicalcareofpatientswithinflammatoryboweldisease AT esmailabej utilityoffecalcalprotectinintherealworldclinicalcareofpatientswithinflammatoryboweldisease AT waelelmatary utilityoffecalcalprotectinintherealworldclinicalcareofpatientswithinflammatoryboweldisease AT harmindersingh utilityoffecalcalprotectinintherealworldclinicalcareofpatientswithinflammatoryboweldisease AT charlesnbernstein utilityoffecalcalprotectinintherealworldclinicalcareofpatientswithinflammatoryboweldisease |